Identification of carriership of GPV in a cancer-predisposition gene may be useful to establish an individualized oncological screening, which would contribute to early detection of possible cancer and thus reduce post-transplant malignancy-associated morbidity and mortality. The gene discussed is GP5; the disease is cancer.